Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Regulatory News (PRTC)

Share Price Information for PureTech (PRTC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 187.80
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 1.40 (0.744%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 187.80
PRTC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

6 Jul 2020 07:00

RNS Number : 0566S
PureTech Health PLC
06 July 2020
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Puretech Health PLC

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii: As of 1 July 2020, Merian Global Investors Limited is owned by Jupiter Fund Management Plc. Any positions in Merian Global Investors Limited are transferred to Jupiter Fund Management Plc.

The disclosure also highlights the full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity detailed within Section 9, following this change of ownership.

X

3. Details of person subject to the notification obligationiv

Name

Jupiter Fund Management Plc

City and country of registered office (if applicable)

4. Full name of shareholder(s) (if different from 3.)v

Name

Northern Trust

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

01/07/2020

6. Date on which issuer notified (DD/MM/YYYY):

03/07/2020

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

5.53%

0%

5.53%

285,512,461

Position of previous notification (if

applicable)

N/A

N/A

N/A

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

GB00BY2Z0H74

N/A

15,799,957

 

N/A

5.53%

SUBTOTAL 8. A

15,799,957

 

5.53%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

N/A

N/A

N/A

N/A

N/A

SUBTOTAL 8. B 1

N/A

N/A

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

N/A

N/A

N/A

N/A

N/A

N/A

SUBTOTAL 8.B.2

N/A

N/A

 

 

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

X

Name

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Jupiter Fund Management Plc

Jupiter Fund Management Group Limited

Jupiter Asset Management Group Limited

Knightsbridge Asset Management Limited

Jupiter Investment Management Group Limited

Jupiter Asset Management Limited

5.53%

0%

5.53%

Jupiter Fund Management Plc

Merian Global Investors Limited

Merian Global Investors (Jersey) Limited

Merian Global Investors (Finance) Limited

Merian Global Investors Holdings Limited

Merian Global Investors (UK) Limited

 

 

 

 

 

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

N/A

The date until which the voting rights will be held

N/A

11. Additional informationxvi

Contact : Claire Rodway

 

Telephone Number : 0203 817 1441

 

Place of completion

London, UK

Date of completion

3rd July 2020

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLRAMLTMTJMBRM
Date   Source Headline
25th May 202112:00 pmRNSPRTC Presents at Jefferies Healthcare Conference
12th May 202112:00 pmRNSPureTech Forms IPF Clinical Advisory Board
28th Apr 20214:08 pmRNSNew PureTech Research Published in Nature Journal
26th Apr 20211:05 pmRNSGelesis Appoints Procter & Gamble Veteran to BOD
15th Apr 20217:00 amRNSFinal Results
12th Apr 202112:00 pmRNSPRTC Presents Data for LYT-210 IO Program at AACR
7th Apr 202112:00 pmRNSPureTech to Present at Two Investor Conferences
7th Apr 202110:15 amRNSAkili Collab to Study Long COVID-Related Brain Fog
26th Mar 202112:02 pmRNSAkili Data Published in Nature Digital Medicine
24th Mar 20217:00 amRNSHolding(s) in Company
18th Mar 20217:00 amRNSDirectorate Change
15th Mar 20217:00 amRNSNotice of Results
3rd Mar 202112:00 pmRNSPRTC Presents at Barclays Healthcare Conference
2nd Mar 20211:01 pmRNSKaruna Prices Approximately $250M Public Offering
25th Feb 20212:00 pmRNSPRTC Publishes Lymphatic Targeting Study for Glyph
25th Feb 20217:00 amRNSKaruna data in New England Journal of Medicine
18th Feb 202112:00 pmRNSPRTC Presents at SVB Leerink Healthcare Conference
10th Feb 20217:05 amRNSVor Closes Over $200M Initial Public Offering
10th Feb 20217:00 amRNSPRTC Receives $118M from Founded Entity Shares
8th Feb 202112:00 pmRNSVedanta Adds Biotech Finance and IR Expert as CFO
5th Feb 202111:46 amRNSPureTech Founded Entity Vor Lists on Nasdaq
5th Feb 20217:00 amRNSHolding(s) in Company
1st Feb 20217:00 amRNSTotal Voting Rights
29th Jan 20217:00 amRNSPureTech Appoints Bharatt Chowrira to BOD
18th Jan 20217:00 amRNSVor Files IPO Registration Statement on Nasdaq
14th Jan 202112:05 pmRNSVor Announces FDA Acceptance of IND Application
14th Jan 202111:50 amRNSAesthetic Med & Dermatology Veterans Join Follica
12th Jan 202111:50 amRNSVedanta Receives $25M Investment from Pfizer Inc
5th Jan 20217:00 amRNSPRTC Appoints Biotech Analyst & Senior Exec as CFO
4th Jan 20217:00 amRNSTotal Voting Rights
21st Dec 202012:00 pmRNSPureTech to Present at JPM and Other Conferences
21st Dec 20207:00 amRNSDirector/PDMR Shareholding
11th Dec 202012:00 pmRNSPRTC Starts LYT-200 Clinical Trial in Solid Tumors
11th Dec 20207:00 amRNSHolding(s) in Company
10th Dec 202012:00 pmRNSLYT-100 Advances to Phase 2a Study in Lymphedema
9th Dec 202012:00 pmRNSFollica Female Hair Loss Academic Study Published
3rd Dec 202012:00 pmRNSPureTech Initiates Ph 2 of LYT-100 in Long COVID
1st Dec 20207:00 amRNSTotal Voting Rights
30th Nov 202012:00 pmRNSPureTech to Host Virtual R&D Day for Investors
27th Nov 20204:41 pmRNSSecond Price Monitoring Extn
27th Nov 20204:37 pmRNSPrice Monitoring Extension
27th Nov 20207:05 amRNSPDMR DEALING - PURCHASE OF SHARES
27th Nov 20207:00 amRNSPDMR DEALING - PURCHASE OF SHARES
24th Nov 202012:00 pmRNSVedanta Appoints Karuna CFO Troy Ignelzi to BOD
23rd Nov 20207:05 amRNSPDMR DEALING - PURCHASE OF SHARES
23rd Nov 20207:00 amRNSDirector/PDMR Shareholding
19th Nov 20207:00 amRNSPDMR DEALING - PURCHASE OF SHARES
18th Nov 20207:00 amRNSPRTC LYT-100 Shows PK & Tolerability Ph1 POC
16th Nov 20207:00 amRNSPureTech to Present at Three Investor Conferences
13th Nov 20205:05 pmRNSGuidance for Exchanging Ordinary Shares into ADSs

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.